Posted by Michael Wonder on 12 Jul 2024
AskBio receives FDA fast track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
11 July 2024 - Bayer AG and Asklepios BioPharmaceutical today announced that the US FDA has granted fast track designation for AB-1005, which is being developed for moderate Parkinson’s disease.
AB-1005 has also been awarded the Innovation Passport, the UK MHRA innovative medicine designation, for the treatment of Parkinson’s disease.
